SCHEMBL16615941

SCHEMBL16615941

Cc1ncc(CNC(=O)c2cnc(CNC(=O)c3ccc(Cl)cc3Cl)cn2)s1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRIN2A Q12879 3/20 0.63
GRIN1 Q05586 2/20 0.63
HPGD P15428 4/20 0.51
POLB P06746 4/20 0.47
RAB9A P51151 2/20 0.44
KMT2A Q03164 1/20 0.44
GRIN2B Q13224 1/20 0.44
THRB P10828 1/20 0.44
RECQL P46063 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
NPC1 O15118 1/20 0.40
LMNA P02545 2/20 0.40
HTT P42858 1/20 0.40
KDM4E B2RXH2 2/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.39
GAA P10253 1/20 0.39
P2RX7 Q99572 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16598153 0.89 GRIN2A (0.67) GRIN2AGRIN1HPGDRAB9AKMT2A
SCHEMBL16615794 0.88 GRIN2A (0.49) GRIN2AGRIN1HPGDPOLBRAB9A
SCHEMBL16615937 0.84 GRIN2A (0.61) GRIN2AGRIN1HPGDKMT2AGRIN2B
SCHEMBL16615814 0.82 GRIN2A (0.61) GRIN2AGRIN1HPGDPOLBRAB9A
SCHEMBL16713084 0.81 GRIN2A (0.54) GRIN2AGRIN1HPGDPOLBRAB9A
SCHEMBL16615945 0.80 GRIN2A (0.77) GRIN2AGRIN1POLBRAB9AKMT2A
SCHEMBL16615832 0.79 GRIN2A (0.78) GRIN2AGRIN1KMT2AGRIN2BL3MBTL1
SCHEMBL16598350 0.78 GRIN2A (0.77) GRIN2AGRIN1RAB9AKMT2AGRIN2B
SCHEMBL16597898 0.78 GRIN2A (0.55) GRIN2AGRIN1HPGDPOLBRAB9A
SCHEMBL16598003 0.78 GRIN2A (0.85) GRIN2AGRIN1KMT2AGRIN2BLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9963434-B2 N-arylmethyl sulfonamide negative modulators of NR2A LUC THERAPEUTICS, INC. (US) 2018-05-08 US disclosed
US-9963434-B2 N-arylmethyl sulfonamide negative modulators of NR2A LUC THERAPEUTICS, INC. (US) 2018-05-08 US disclosed
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A NOVARTIS AG (CH) 2016-10-27 US disclosed
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A NOVARTIS AG (CH) 2016-10-27 US disclosed
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. 2015-05-21 US disclosed
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. 2015-05-21 US disclosed
WO-2015048503-A2 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. (US) 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A GRIN2A, GRIN2B, NR2C2 GRIN2A 1/4885GRIN1 5/4885HPGD 3080/4885
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A GRIN2A, GRIN2B, NR2C2 GRIN2A 1/4885GRIN1 5/4885HPGD 3080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.